KLK3 and neoplasm: This first adaptive trial enrolled a small cohort of metastatic castrate-resistant prostate cancer patients, contingent upon a minimum of 50% drop in the level of prostate-specific antigen biomarker (PSA; a proxy for tumor burden) under abiraterone administration.